ENDRA Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for ENDRA Life Sciences (NDRA).

Price Target Range — 5 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$25Upside to Avg. PT+378.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 1, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$27→$25
Dec 8, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$38→$30
Sep 22, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$46→$38
May 30, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$50→$46
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$75→$50
Jun 7, 2024	Ascendiant Capital	Edward Woo	PT Cut	Buy	$10→$8

More with Benzinga EdgeGet Access

Analyst Ratings News

Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know

Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $27 to $25.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $38 to $30.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $46 to $38.

Benzinga Newsdesk

Microchip Technology To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46

Ascendiant Capital analyst Edward Woo maintains ENDRA Life Sciences (NASDAQ:NDRA) with a Buy and lowers the price target from $50 to $46.

Benzinga Newsdesk

ENDRA Life Sciences Inc

ENDRA Life Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38

Microchip Technology To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46

People Also Watch

People Also Watch

ENDRA Life Sciences Inc

ENDRA Life Sciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know

PROAscendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

PROAscendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

PROAscendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38

Microchip Technology To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Friday

PROAscendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $38

PRO
Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $46